Downstream or upstream P2Y12 receptor blockers in NSTE-ACS

31 August 2020 (10:05 - 10:15)

Organised by:

Video

Slides

Sign in for access options

About the speaker

Professor Giuseppe Tarantini

University of Padua, Padova (Italy)

3 More presentations in this session

Presentation thumbnail

Online session - Latest Randomized Results on Antiplatelet Therapy - Host and Discussant

Professor M. Roffi (Geneva, CH)

Presentation thumbnail

The effect of one year postoperative ticagrelor in addition to aspirin on saphenous vein graft patency in patients undergoing CABG – a randomized, multi-center, double-blind, placebo-controlled trial.

Miss L. Willemsen (Nieuwegein, NL)

Presentation thumbnail

Prasugrel based de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: results from the HOST-REDUCE-POLYTECH-ACS trial

Doctor H. Kim (Seoul, KR)

Access the full session

Session thumbnail

Latest Randomized Results on Antiplatelet Therapy

The Event

ESC Congress 2020

31 August 2020 10:05 CET

You may be interested in

Congress Presentation

Impact of P2Y12 inhibitor pretreatment before coronary angiography in high risk NSTE-ACS: A comparative cohort analysis

21 March 2026

Congress Session

Dual antiplatelet therapy titration after percutaneous coronary intervention: when to escalate, de-escalate, withdraw, and more

28 August 2023

Congress Presentation

Selatogrel, the reversible and specific P2Y12 receptor antagonist, does not interfere with haemostasis

1 September 2020

Congress Presentation

Feasibility and outcomes of tailored antiplatelet therapy at a safety-net hospital

21 March 2026

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources